References
- Cowings PS, Toscano WB, DeRoshia C, Miller NE. Promethazine as a motion sickness treatment. Aviation & Space Environmental Medicine 2000; 71: 1013–1022
- Davis JR, Vanderploeg HM, Santy PA, Jennings RT, Stewart DF. Space motion sickness during 24 flights of the space shuttle. Aviation & Space Environmental Medicine 1988; 59: 1185–1189
- Illum L. Nasal drug delivery-possibilities, problems, and solutions. Journal of Controlled Release 2003; 87: 187–198
- Lackner JR, Graybiel A. Use of promethazine to hasten adaptation to provocative motion. Journal of Clinical Pharmacology 1994; 34: 644–648
- Marttin E, Verhoef JC, Spies F. The effect of methylated beta-cyclodextrins on the tight junctions of the rat nasal respiratory epithelium: Electron microscopic and confocal laser scanning microscopic visualization studies. Journal of Controlled Release 1999; 57: 205–213
- McDonough JA. Microcapsule formulation: Controlled release microcapsule formulation design for nasal delivery. Drug Delivery Technology 2004; 4: 44–47
- Persyn JT, McDonough JA, Nino JA, Dixon H, Boland EJ. Mucosal delivery of cytotoxic therapeutic agents: Response of rat nasal mucosa to microencapsulated ethopropazine HCl enantiomer. Journal of Microencapsulation 2005; 22: 737–744
- Ramanathan R, Geary RS, Bourne DWA, Putcha L. Bioavailability of intranasal promethazine dosage forms in dogs. Pharmacology Research 1998; 38: 35–39
- Takeda N, Morita M, Hasegawa S. Neuropharmacology of motion sickness and emesis. Acta Otolaryngologica (Stockholm) 1993; 501(Suppl)10–15